Solaris Resources Inc. (CVE:SLS – Get Free Report) shares fell 2.7% on Tuesday . The company traded as low as C$5.95 and last traded at C$6.15. 53,313 shares traded hands during trading, a decline of 60% from the average session volume of 132,199 shares. The stock had previously closed at C$6.32.
Wall Street Analyst Weigh In
Separately, Maxim Group downgraded shares of Solaris Resources from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 25th.
Read Our Latest Research Report on SLS
Solaris Resources Stock Performance
Solaris Resources Company Profile
SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Read More
- Five stocks we like better than Solaris Resources
- What is the Euro STOXX 50 Index?
- Analyst Downgrades Joby, But Overlooks Major Regulatory Wins
- Are Penny Stocks a Good Fit for Your Portfolio?
- U.S. Steel Stock Burns the Bears With Surprise Upside Move
- NYSE Stocks Give Investors a Variety of Quality Options
- Lululemon, UNH, Enphase: Bad News, Good Opportunity?
Receive News & Ratings for Solaris Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solaris Resources and related companies with MarketBeat.com's FREE daily email newsletter.
